GLP-1 Vision Loss Lawsuits: Ozempic, Wegovy, and NAION Optic Nerve Injury Claims

Patients who were prescribed Ozempic (semaglutide), Wegovy (semaglutide), Mounjaro (tirzepatide), or other GLP-1 receptor agonist medications to treat type 2 diabetes or for weight loss may be at risk of vision loss or blindness from a condition known as non-arteritic anterior ischemic optic neuropathy (NAION)….
By: Hissey, Mulderig & Friend, PLLC